Insider Transactions and Merger Event

This filing details insider transactions by Tobin Schilke, Chief Financial & Infra. Officer of Crinetics Pharmaceuticals, Inc., on September 1, 2026. These transactions are related to the company's merger with Vertex Pharmaceuticals Incorporated, effective the same date. Schilke disposed of 7,956 shares of common stock at $85.00 per share, and subsequently disposed of the remaining 71,471 shares at the same price, as part of the merger consideration. Additionally, stock options were exercised and canceled. 80,000 stock options with an exercise price of $33.75 were canceled and converted into cash, with a reported value of $51.25 per share. 50,000 stock options with an exercise price of $43.79 were also canceled and converted into cash, with a reported value of $41.21 per share. These actions are in accordance with the merger agreement where all outstanding shares and vested options were converted into the right to receive $85.00 per share in cash.